Tenax Therapeutics Achieves 230 Patient Randomization Target in LEVEL Study
"We are pleased to announce that we have recently achieved our randomization target of 230 patients in the Phase 3 LEVEL study. As we strive to make significant progress executing on our registrational LEVEL program, achievement of this important milestone demonstrates our team's commitment to rapidly advancing TNX-103," said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. "The screening period for LEVEL has closed. Patients already screening will have the opportunity to qualify for randomization, which we anticipate finishing this month. We expect to share initial results from LEVEL in the third quarter of 2026."
Trade with 70% Backtested Accuracy
Analyst Views on TENX
About TENX
About the author
Tenax Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Tenax Therapeutics reported a Q4 GAAP EPS of -$0.38, beating expectations by $0.03, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Reserves Status: As of December 31, 2025, Tenax's cash and cash equivalents stood at $97.6 million, which is expected to fund the company's operations through 2027, ensuring the continuity of its R&D projects.
- Future Potential Outlook: Despite the current negative earnings, Tenax is viewed as a speculative buy due to improving clinical trial results, which could lead to a higher valuation for the company.
- Market Evaluation: Seeking Alpha's quant rating on Tenax Therapeutics reflects market interest in its future developments, prompting investors to closely monitor the company's performance in upcoming quarters and its impact on stock price.
Tenax Therapeutics (TENX) Price Target Raised by 12.22% to 25.76
Price Target Update: The average one-year price target for Tenax Therapeutics (NasdaqCM:TENX) has been revised to $25.76 per share, reflecting a 12.22% increase from the previous estimate of $22.95, with a potential range between $20.20 and $31.50 per share.
Fund Sentiment: There are currently 48 funds reporting positions in Tenax Therapeutics, marking a 20% increase in ownership over the last quarter, with total shares owned by institutions rising by 109.94% to 4,753K shares.
Significant Shareholder Activity: Ikarian Capital and Boothbay Fund Management both increased their holdings by 100%, while VR Adviser raised its stake by 77.48%, indicating strong interest from institutional investors.
Fintel Overview: Fintel provides comprehensive investment research tools, including fundamentals, analyst reports, and ownership data, aimed at individual investors and small hedge funds to enhance their trading strategies.
Tenax Initiates Global LEVEL-2 Study, Enrollment Expected by 2027
- Trial Design Confirmation: Tenax Therapeutics' LEVEL study underwent a Blinded Sample Size Re-estimation, demonstrating over 90% statistical power to detect a 25-meter change in 6-minute walk distance, which bolsters confidence in the company's drug development in heart failure.
- Enrollment Progress: The LEVEL study is expected to complete enrollment in the first half of 2026, indicating smooth clinical trial progress in cardiopulmonary therapies, allowing timely access to critical data to support further development.
- New Study Initiation: The LEVEL-2 study has been initiated, aiming to enroll approximately 540 patients, with completion expected by the end of 2027, which will provide crucial data to support the market potential of TNX-103.
- Long-term Study Plan: Tenax will also conduct a long-term open-label extension study to ensure participants continue receiving TNX-103 after trial completion, enhancing patient reliance on the company's product.
Tenax Initiates Global LEVEL-2 Study, Enrollment Expected by 2027
- Trial Design Optimization: The blinded sample size re-estimation of the LEVEL study indicates a power exceeding 90% to detect changes in 6-minute walk distance, which instills confidence for subsequent clinical trials while confirming the unchanged target enrollment.
- Enrollment Timeline: The LEVEL study is expected to complete enrollment in the first half of 2026, while the LEVEL-2 study plans to enroll approximately 540 patients by the end of 2027, demonstrating the company's ongoing commitment to heart disease treatment.
- Global Expansion: The LEVEL-2 study has selected over 100 clinical trial sites across 15 countries, aiming to enhance enrollment efficiency through rigorous patient assessment methods, thereby accelerating the development of new therapies.
- Long-term Research Plans: Tenax also plans to initiate a long-term open-label extension study, providing continued access to TNX-103 for patients enrolled in levosimendan clinical trials, ensuring treatment availability post-study completion.
Tenax Therapeutics: Overview of Q3 Earnings
Company Performance: Tenax Therapeutics Inc. reported a loss of $15.8 million in its third quarter, equating to a loss of 40 cents per share.
Market Expectations: The reported loss was better than Wall Street expectations, which anticipated a loss of $1.33 per share according to analysts surveyed by Zacks Investment Research.
Tenax Therapeutics: Q2 Earnings Snapshot
Financial Performance: Tenax Therapeutics Inc. reported a loss of $10.8 million in its second quarter, equating to 27 cents per share.
Market Expectations: The company's results exceeded Wall Street expectations, which anticipated a larger loss of 50 cents per share according to analysts from Zacks Investment Research.
Tenax Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Tenax Therapeutics reported a Q4 GAAP EPS of -$0.38, beating expectations by $0.03, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Reserves Status: As of December 31, 2025, Tenax's cash and cash equivalents stood at $97.6 million, which is expected to fund the company's operations through 2027, ensuring the continuity of its R&D projects.
- Future Potential Outlook: Despite the current negative earnings, Tenax is viewed as a speculative buy due to improving clinical trial results, which could lead to a higher valuation for the company.
- Market Evaluation: Seeking Alpha's quant rating on Tenax Therapeutics reflects market interest in its future developments, prompting investors to closely monitor the company's performance in upcoming quarters and its impact on stock price.
Tenax Therapeutics (TENX) Price Target Raised by 12.22% to 25.76
Price Target Update: The average one-year price target for Tenax Therapeutics (NasdaqCM:TENX) has been revised to $25.76 per share, reflecting a 12.22% increase from the previous estimate of $22.95, with a potential range between $20.20 and $31.50 per share.
Fund Sentiment: There are currently 48 funds reporting positions in Tenax Therapeutics, marking a 20% increase in ownership over the last quarter, with total shares owned by institutions rising by 109.94% to 4,753K shares.
Significant Shareholder Activity: Ikarian Capital and Boothbay Fund Management both increased their holdings by 100%, while VR Adviser raised its stake by 77.48%, indicating strong interest from institutional investors.
Fintel Overview: Fintel provides comprehensive investment research tools, including fundamentals, analyst reports, and ownership data, aimed at individual investors and small hedge funds to enhance their trading strategies.
Tenax Initiates Global LEVEL-2 Study, Enrollment Expected by 2027
- Trial Design Confirmation: Tenax Therapeutics' LEVEL study underwent a Blinded Sample Size Re-estimation, demonstrating over 90% statistical power to detect a 25-meter change in 6-minute walk distance, which bolsters confidence in the company's drug development in heart failure.
- Enrollment Progress: The LEVEL study is expected to complete enrollment in the first half of 2026, indicating smooth clinical trial progress in cardiopulmonary therapies, allowing timely access to critical data to support further development.
- New Study Initiation: The LEVEL-2 study has been initiated, aiming to enroll approximately 540 patients, with completion expected by the end of 2027, which will provide crucial data to support the market potential of TNX-103.
- Long-term Study Plan: Tenax will also conduct a long-term open-label extension study to ensure participants continue receiving TNX-103 after trial completion, enhancing patient reliance on the company's product.
Tenax Initiates Global LEVEL-2 Study, Enrollment Expected by 2027
- Trial Design Optimization: The blinded sample size re-estimation of the LEVEL study indicates a power exceeding 90% to detect changes in 6-minute walk distance, which instills confidence for subsequent clinical trials while confirming the unchanged target enrollment.
- Enrollment Timeline: The LEVEL study is expected to complete enrollment in the first half of 2026, while the LEVEL-2 study plans to enroll approximately 540 patients by the end of 2027, demonstrating the company's ongoing commitment to heart disease treatment.
- Global Expansion: The LEVEL-2 study has selected over 100 clinical trial sites across 15 countries, aiming to enhance enrollment efficiency through rigorous patient assessment methods, thereby accelerating the development of new therapies.
- Long-term Research Plans: Tenax also plans to initiate a long-term open-label extension study, providing continued access to TNX-103 for patients enrolled in levosimendan clinical trials, ensuring treatment availability post-study completion.
Tenax Therapeutics: Overview of Q3 Earnings
Company Performance: Tenax Therapeutics Inc. reported a loss of $15.8 million in its third quarter, equating to a loss of 40 cents per share.
Market Expectations: The reported loss was better than Wall Street expectations, which anticipated a loss of $1.33 per share according to analysts surveyed by Zacks Investment Research.
Tenax Therapeutics: Q2 Earnings Snapshot
Financial Performance: Tenax Therapeutics Inc. reported a loss of $10.8 million in its second quarter, equating to 27 cents per share.
Market Expectations: The company's results exceeded Wall Street expectations, which anticipated a larger loss of 50 cents per share according to analysts from Zacks Investment Research.
